Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Avoca Quality Consortium Announces 2013 Key Initiatives

Published: Friday, January 25, 2013
Last Updated: Friday, January 25, 2013
Bookmark and Share
Eli Lilly & Co. and Pfizer, Inc. continue as lead Consortium sponsors.

The Avoca Group announced the Avoca Quality Consortium’s 2013 key initiatives. Building upon a successful launch year, the Avoca Quality Consortium will implement additional initiatives aimed at further enabling members to optimize approaches for proactive quality management of outsourced clinical trials.

Formed in January of 2012 with 29 members, The Avoca Quality Consortium brings together executives from pharma, biotech, and clinical research organizations (CROs) to accelerate the development of best practice approaches to quality management. Over the past year, the Consortium successfully completed the creation of a Clinical Quality Agreement template and a Quality Metrics initiative.

“Our overarching goal is to help our diverse members strike the right balance between meeting timelines, ensuring cost containment and achieving the highest level of quality in their clinical trials,” explained Patricia Leuchten, President and CEO of Avoca. “We made tremendous progress during our first year and are now poised to expand the scope of this critically important work.”

For 2013, the Quality Consortium will conduct a consortium-wide research assessment focused on managing risk in outsourced clinical trials. This will include an assessment of Consortium members’ approaches to managing risk compared to the overall industry’s approach.

“At a time of increasing regulatory expectations, industry collaboration to raise the bar on quality in critical trials is more important than ever,” said Jeff Kasher, Ph.D., Vice President, Clinical Trial: Materials, Implementation, and Transformation, Eli Lilly Co. “Our first year work produced very practical tools, which many members have already put into use. Our 2013 focus on guidelines and tools for effective oversight will continue in the same spirit: research that leads to useable tools to support proactive quality management.”

Research and work on leading practices in proactive quality management serve as the two pillars of the Avoca Quality Consortium. Members of the Avoca Quality Consortium will receive 2013 guidelines and tools focused on effective oversight, revisions and refinements to its quality agreement and metrics tools, Avoca research reports, participation in the May Summit and Fall Working Sessions, participation in regular WebEx Meetings and updates on work related to avenues for operationalizing approaches to proactive quality management.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Trying to Conceive Soon After a Pregnancy Loss May Increase Chances of Live Birth
NIH study finds no reason for delaying pregnancy attempts after a loss without complications.
BRCA1 Deficiency Increases the Sensitivity of Ovarian Cancer Cells to Auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Shingles Vaccine Helps Protect Older Patients with End-stage Renal Disease
Kaiser Permanente study advances knowledge about safety and effectiveness of vaccine commonly given to older adults.
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!